Abstract | BACKGROUND: METHODS AND RESULTS: Levels of GDF-15 were measured at pre-specified time-points (baseline and at days 2, 5, 14, and 60) in patients enrolled in the placebo-controlled RELAXin in Acute Heart Failure (RELAX-AHF) study, which examined the effect of serelaxin in 1161 patients with AHF, systolic blood pressure >125 mmHg, and mild to moderate renal impairment. Neither baseline nor changes in GDF-15 were associated with the degree of dyspnoea or dyspnoea relief. After adjustment for baseline characteristics, baseline GDF-15 was not associated with the composite endpoint of heart failure or renal failure (HF/RF) readmission at 60 days/cardiovascular (CV) death or CV death at 180 days. In contrast, larger increases in GDF-15 levels at days 2 and 14 were associated with a greater risk of 60-day HF/RF rehospitalizations/CV death and CV death at 180 days. Serelaxin treatment was associated with significantly larger decreases of GDF-15 at days 2 and 5 than placebo. CONCLUSIONS: In AHF patients enrolled in the RELAX-AHF study, increases in GDF-15 levels, but not baseline measurements, were associated with a greater likelihood of adverse outcomes. Serelaxin administration was associated with greater decreases in GDF-15 compared with placebo.
|
Authors | Gad Cotter, Adriaan A Voors, Margaret F Prescott, G Michael Felker, Gerasimos Filippatos, Barry H Greenberg, Peter S Pang, Piotr Ponikowski, Olga Milo, Tsushung A Hua, Min Qian, Thomas M Severin, John R Teerlink, Marco Metra, Beth A Davison |
Journal | European journal of heart failure
(Eur J Heart Fail)
Vol. 17
Issue 11
Pg. 1133-43
(Nov 2015)
ISSN: 1879-0844 [Electronic] England |
PMID | 26333529
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 The Authors European Journal of Heart Failure © 2015 European Society of Cardiology. |
Chemical References |
- Cardiovascular Agents
- Growth Differentiation Factor 15
- Peptide Fragments
- Recombinant Proteins
- pro-brain natriuretic peptide (1-76)
- serelaxin protein, human
- Natriuretic Peptide, Brain
- Relaxin
|
Topics |
- Acute Disease
- Aged
- Aged, 80 and over
- Cardiovascular Agents
(administration & dosage)
- Double-Blind Method
- Female
- Growth Differentiation Factor 15
(blood)
- Heart Failure
(blood, diagnosis, drug therapy, mortality, physiopathology)
- Hospitalization
- Humans
- Male
- Middle Aged
- Mortality
- Natriuretic Peptide, Brain
(blood)
- Peptide Fragments
(blood)
- Recombinant Proteins
(administration & dosage)
- Relaxin
(administration & dosage)
- Severity of Illness Index
- Statistics as Topic
- Symptom Flare Up
- Treatment Outcome
|